Eton Pharmaceutcials, Inc. Common Stock (ETON) is a publicly traded Healthcare sector company. As of May 20, 2026, ETON trades at $33.86 with a market cap of $889.98M and a P/E ratio of -651.88. ETON moved +1.12% today. Year to date, ETON is +102.28%; over the trailing twelve months it is +68.06%. Its 52-week range spans $5.40 to $33.41. Analyst consensus is strong buy with an average price target of $45.67. Rallies surfaces ETON's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Eton Pharmaceuticals Gains U.S. Rights to IMPAVIDO with September 2026 Launch: Eton Pharmaceuticals has secured exclusive U.S. commercialization rights for IMPAVIDO (miltefosine), the only FDA-approved oral therapy for visceral, cutaneous, and mucosal leishmaniasis. The supply and distribution deal with Knight’s affiliate expands Eton’s orphan drug portfolio and positions the company to serve patients aged 12 and older across specialized leishmaniasis indications.
| Metric | Value |
|---|---|
| Price | $33.86 |
| Market Cap | $889.98M |
| P/E Ratio | -651.88 |
| EPS | $-0.05 |
| Dividend Yield | 0.00% |
| 52-Week High | $33.41 |
| 52-Week Low | $5.40 |
| Volume | 414.81K |
| Avg Volume | 0 |
| Revenue (TTM) | $86.93M |
| Net Income | $-1.48M |
| Gross Margin | 54.77% |
3 analysts cover ETON: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $45.67.